Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAF V600-mutant advanced melanoma
MOH_2017-04-23_000312Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab, cobimetinib and vemurafenib in melanoma (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Dec 2016; status: completed.
02
Drugs
atezolizumabcobimetinibvemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2017-04-23_000312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-23_000312.